www.bioscience.co.uk
Sales & Support: +44 (0)1223 316 855

*

Anti-α4β7 Integrin (Vedolizumab), Humanized Antibody

Supplier:
Catalogue number:
A2140-100
Size:
100 µg
Product is available in:
  • UK
  • Ireland
  • Europe
  • USA
  • Rest of World
£581.00 Estimated delivery Wed 30 Jun
Shipping is calculated in checkout

Vedolizumab is a recombinant humanised IgG1 monoclonal antibody that selectively targets α4β7 integrin expressed on the surface of T and B cell lymphocytes and prevents the association of the integrin with its ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1). This inhibits the inflammatory activity of the lymphocytic cells and its migration into the gut lamina propria and gut-associated lymphoid tissue (GALT). Vedolizumab was developed by Millennium Pharmaceuticals and received FDA approval in 2014 for the treatment of ulcerative colitis and Crohn’s disease. Vedolizumab is marketed under the trade name of Entyvio®

Product Type:

Antibodies

Species Reactivity:

Human

Storage Temp:

-80°C

Antibody Host:

Recombinant

Antibody Isotype:

IgG1, kappa

Formulation:

In PBS, pH 7.5

Antibody Type:

Monoclonal

UNSPSC Code:

12352203

Details Cat number & supplier Size Price
Anti-VEGFR2 (Ramucirumab), Human IgG1 Antibody A2139-100 · BioVision
A2139-100
BioVision
100 µg £581.00
100 µg
view
Anti-TNF-α (Golimumab), Human IgG1 Antibody A2141-100 · BioVision
A2141-100
BioVision
100 µg £581.00
100 µg
view
Anti-C5 (Eculizumab), Humanized Antibody A2138-100 · BioVision
A2138-100
BioVision
100 µg £530.00
100 µg
view
Anti-TNF-α (Certolizumab Pegol), Humanized Antibody A2142-100 · BioVision
A2142-100
BioVision
100 µg £581.00
100 µg
view
Anti-IL-12β (Ustekinumab), Human IgG1 Antibody A2137-100 · BioVision
A2137-100
BioVision
100 µg £581.00
100 µg
view
Anti-IL-6 (Siltuximab), Chimeric Antibody A2143-100 · BioVision
A2143-100
BioVision
100 µg £581.00
100 µg
view
Anti-VEGF-A Humanized Antibody A2136-100 · BioVision
A2136-100
BioVision
100 µg £581.00
100 µg
view